Literature DB >> 25839656

Metabolic signatures of renal cell carcinoma.

Hwee Ying Lim1, Yin Mun Yip1, Edmund Chiong2, Ho Yee Tiong2, Barry Halliwell1, Kesavan Esuvaranathan2, Kim Ping Wong3.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by the constitutive up-regulation of the hypoxia inducible factor-1. One of its target enzymes, pyruvate dehydrogenase (PDH) kinase 1 (PDHK1) showed increased protein expression in tumor as compared to patient-matched normal tissues. PDHK1 phosphorylated and inhibited PDH whose enzymatic activity was severely diminished, depriving the TCA cycle of acetylCoA. We and others have shown a decrease in the protein expressions of all respiratory complexes alluding to a compromise in oxidative phosphorylation (OXPHOS). On the contrary, we found that key parameters of OXPHOS, namely ATP biosynthesis and membrane potential were consistently measurable in mitochondria isolated from ccRCC tumor tissues. Interestingly, an endogenous mitochondrial membrane potential (MMP) was evident when ADP was added to mitochondria isolated from ccRCC but not in normal tissues. In addition, the MMP elicited in the presence of ADP by respiratory substrates namely malate/glutamate, succinate, α-ketoglutarate and isocitrate was invariably higher in ccRCC. Two additional hallmarks of ccRCC include a loss of uncoupling protein (UCP)-2 and an increase in UCP-3. Based on our data, we proposed that inhibition of UCP3 by ADP could contribute to the endogenous MMP observed in ccRCC and other cancer cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clear cell renal cell carcinoma (ccRCC); Mitochondrial membrane potential (MMP); Oxidative phosphorylation (OXPHOS); Uncoupling protein 2 (UCP2); Uncoupling protein 3 (UCP3); Warburg effect

Mesh:

Substances:

Year:  2015        PMID: 25839656     DOI: 10.1016/j.bbrc.2015.03.130

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma.

Authors:  Surangkana Sanmai; Tanakorn Proungvitaya; Temduang Limpaiboon; Daraporn Chua-On; Wunchana Seubwai; Sittiruk Roytrakul; Sopit Wongkham; Chaisiri Wongkham; Ongart Somintara; Sakkarn Sangkhamanon; Siriporn Proungvitaya
Journal:  Oncol Lett       Date:  2019-03-22       Impact factor: 2.967

2.  The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol.

Authors:  Burton M Berkson; Francisco Calvo Riera
Journal:  Integr Cancer Ther       Date:  2017-12-19       Impact factor: 3.279

3.  VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.

Authors:  Bojana B Ilic; Jadranka A Antic; Jovana Z Bankovic; Ivana T Milicevic; Gordana S Rodic; Dusan S Ilic; Cane D Tulic; Vera N Todorovic; Svetozar S Damjanovic
Journal:  J Med Biochem       Date:  2018-01-01       Impact factor: 3.402

Review 4.  The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.

Authors:  Ana Lameirinhas; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo
Journal:  Genes (Basel)       Date:  2019-04-02       Impact factor: 4.096

Review 5.  Impact of intracellular ion channels on cancer development and progression.

Authors:  Roberta Peruzzo; Lucia Biasutto; Ildikò Szabò; Luigi Leanza
Journal:  Eur Biophys J       Date:  2016-06-11       Impact factor: 1.733

6.  The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.

Authors:  Damien Ambrosetti; Maeva Dufies; Bérengère Dadone; Matthieu Durand; Delphine Borchiellini; Jean Amiel; Jacques Pouyssegur; Nathalie Rioux-Leclercq; Gilles Pages; Fanny Burel-Vandenbos; Nathalie M Mazure
Journal:  PLoS One       Date:  2018-02-26       Impact factor: 3.240

7.  Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis.

Authors:  Qian Zheng; Pengfei Li; Xin Zhou; Yulong Qiang; Jiachen Fan; Yan Lin; Yurou Chen; Jing Guo; Fan Wang; Haihua Xue; Jie Xiong; Feng Li
Journal:  Theranostics       Date:  2021-08-04       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.